Orion (ORINY) Cut to “Strong Sell” at Zacks Investment Research

Orion (OTCMKTS:ORINY) was downgraded by Zacks Investment Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Orion Oyj is a pharmaceutical company. It develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company’s core therapy consists of central nervous system disorders, oncology and respiratory. Its product pipeline includes inhaled Easyhaler(R) pulmonary drugs. Orion Oyj is headquartered in Espoo, Finland. “

Shares of Orion (OTCMKTS ORINY) opened at $15.65 on Thursday. Orion has a 52 week low of $15.65 and a 52 week high of $21.17.

TRADEMARK VIOLATION WARNING: “Orion (ORINY) Cut to “Strong Sell” at Zacks Investment Research” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/15/orion-oriny-cut-to-strong-sell-at-zacks-investment-research.html.

About Orion

Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs.

Get a free copy of the Zacks research report on Orion (ORINY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply